BioSpace News Archive

BridgeBio Pharma, Inc. announced that the proof-of-concept Phase 2b data evaluating the effects of orally-administered encaleret on mineral homeostasis in patients with ADH1 were published in the New England Journal of Medicine in partnership with the National Institutes of Health (NIH).

Transgene and BioInvent International AB announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of new analyses from the MAVENCLAD® tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis experienced sustained reduction in serum neurofilament light chain, indicating that MAVENCLAD reduced neuronal injury over two years.

Bayer AG announced the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale.

Swedish biotech company Salipro Biotech AB and Estonian biotechnology company Icosagen announced that they entered into a multi-target antibody research agreement to advance drug discovery programs against several challenging membrane proteins, including G protein-coupled receptors and solute carrier transporters.

Oculis Holding AG announced that Professor Ramin Tadayoni, M.D., Ph.D., presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress, which took place October 5-8, 2023 in Amsterdam, the Netherlands.

A slate of new initiatives to support locally led innovation was announced in Dakar by the Bill & Melinda Gates Foundation and its partners at the Grand Challenges Annual Meeting.

Merck, known as MSD outside of the United States and Canada, announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer met its dual primary endpoint of overall survival.

Zevra Therapeutics, Inc. today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023.

Windtree Therapeutics, Inc. today announced that Craig Fraser, President and Chief Executive Officer, will be participating in a panel discussion titled, “Cardiac Kids: Late-Stage Advancement for Cardiovascular Disorders,” at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023.